Journal of Bioequivalence & Bioavailability

Joel Posener

Publications

• Research Article
  An Evaluation of the Potential of Cytochrome P450 3A4-Mediated Drug- Drug Interactions with Desvenlafaxine Use
  Author(s): Alice Nichols, Yali Liang, Kyle Matschke, Jeff Paul, Jessica Behrle, Joel Posener, Alain Patat, Shannon Lubaczewski, Gabriel Braley and Tanya RameyAlice Nichols, Yali Liang, Kyle Matschke, Jeff Paul, Jessica Behrle, Joel Posener, Alain Patat, Shannon Lubaczewski, Gabriel Braley and Tanya Ramey
  
  A series of 3 open-label, 2-period, sequential studies were conducted to assess the impact of desvenlafaxine on cytochrome P450 3A4 (CYP3A4) enzyme-mediated metabolism, and the effect of CYP3A4 inhibition on desvenlafaxine metabolism. Study 1 evaluated a single dose of desvenlafaxine 400 mg administered alone or with a CYP3A4 inhibitor (ketoconazole [400 mg/d for 8 days]). Studies 2 and 3 evaluated a single dose of CYP3A4 substrate (midazolam [4 mg]) administered alone or with multiple doses of desvenlafaxine 400 mg and 50 mg (the recommended therapeutic dose), respectively, to assess the potential inhibitory effect of desvenlafaxine. In study 1, desvenlafaxine peak plasma concentration (Cmax) and area under the plasma concentration-versus-time curve (AUC) geometric least-squares mean ratios (desvenlafaxine and ketoconazole vs. desvenlafaxine alone) were 108% (90% confidence interval .. View More»
  DOI: 10.4172/jbb.1000134

  Abstract PDF